













Overview

- □ **Huvepharma ITALIA S.R.L.** is a newly established company, 100% owned by Huvepharma EOOD, a private Bulgarian company owned by the Domuschiev family.
- □ Huvepharma EOOD is a fast growing, pharmaceutical company globally organized to develop, manufacture and commercialize products for human and animal health

HUVEPHARMA stands for:

HUman &

VEterinary

PHARMAceuticals



Huvepharma Italia S.R.L.


- □ Huvepharma ITALIA S.R.L. was established in 2015 with the acquisition of the Sanofi facility located in Garessio (CN).
- □ Huvepharma ITALIA S.R.L.'s focus is the development, production and commercialization of advanced intermediates and API manufactured by chemical synthesis.
- Huvepharma ITALIA S.R.L.'s plan is to:
 - invest in high-potency development and production assets,
 - complete the strategic offer for start-up companies looking for qualified and FDA approved companies,
 - □ be reliable and qualified partner from Phase 1 through commercial phase.



Huvepharma History

Huvepharma EOOD is a young European company (founded in1999), nevertheless possessing consolidated and recognized fermentation knowhow and capabilities owing to the acquisition of companies with over 60 years of experience (f.ex.: BalkanPharma and Biovet).







World presence





2 | Garessio Facilities





Garessio Facilities

Production plant



The Garessio facility is specialized in the development, industrialization and production of Active Pharmaceutical Ingredients and API-intermediates via synthetic chemistry







Garessio Facilities

Location



The facility is located in NW Italy, well connected to multiple international Airports



Garessio Facilities

History

1894:

Corporate

Establishment of the Garessio chemical plant, with a surface of 8,000sq.m. and 70 operators.



1929:

 The pharmaceutical division takes the name of Lepetit S.A.



1964:

The US group Dow Chemical acquires a majority stake in Lepetit.



1981 - 1999:

After successive mergers, the entity, renamed MMD is sold to the German group Hoechst, and becomes Aventis Pharma in 1999. Aventis

2005:

Sanofi S.p.A. in 2014.



2016:

Huvepharma® Italia S.R.L. is established



1894 1903 1929 1930 1935 - 1949 1964 1982-1983 1981-1999 2005 2012 2016

1903:

Start of production of Almateina, the first pharmaceutical product produced at an industrial scale in Italy.



1930:

The Garessio Site produces more than 10,000 tons of APIs, chestnut extracts, tanning extracts and inks.



1935 - 1949:

The site progressively extends its production to the synthesis of vitamin D, K, PP, folic acid and Chloramphenicol, the first antibiotic by synthesis produced in Italy.

1982-1983:

Implementation of several new productions in the Garessio Site, incl. Urokinase. thrombolytics, Terfenadine and antihistaminics.



Production of SSArt with innovative photooxydation technology



Long-established player in the pharma-chemical market with a strongly recognized experience in introducing and developing new technologies












An autonomous asset with room for expansion

Production Facilities

5 production bldgs. 8 production lines 3 Solvents recovery units 100 reactors (total vol. 700 cu.m) 97 tanks (3,000 m³) in several tank farms



Expansion Areas

Available plot of land of 27,500sq.m.

Building 3 currently unused

Expansion area in Building 7 (with a part currently unused)

R&D Facilities

Equipped labs.

1 pilot building

1 very flexible pilot line

Warehouses

8 warehouses

Other Facilities

Administration: site direction, engineering, quality, HR, controlling Canteen Parking Guest house WWTP Thermal Oxidizer



Excellence in process and in technologies

- Complex chemical reactions in large scale:
 - Catalytic hydrogenations (homogeneous, etherogeneous)
 - various catalysts (Ru, Rh, Pd)
 - □ up to 50 bar
 - □ up to 10 m3
 - Catalytic carbonylation with CO gas
 - ☐ Grignard reactions, up to 8 cu m
 - Friedel Crafts
 - Gas liquid reactions (by HCl gas)
 - Peroxide handling (RM, intermediates and finished products)
 - Photo-oxidation
 - Bromination

- Crystallization controlled by Fiber Optics
- Separation of optical isomers
- Production lines 50% computerized
- Cogeneration, thermal-electrical (back pressure turbine)



R&D qualified team

In addition to the Pilot Plant building with relatively small scale equipment: 19 SS and glass lined reactors (total 59 m³), hastelloy centrifuge and dryer, clean packaging room:

- Process Development Laboratories: two laboratories dedicated to development activities with HPLC, GC, etc.
- Process development / optimization
- □ Analytical method development
- ☐ Stability program for API and Intermediates
- □ Reference standards preparation expertise
- Process validation



Consolidated and qualified Quality organization

Quality Control

- Sampling
- Testing and Release of RMs
- Release tests for INT and API
- In-process control
- Reference Standards management
- Retained samples
- Stability programs

Quality Assurance

- Release INT and API
- Batch record review
- Deviation management
- Validation and Qualification
- Annual Product Review
- SOPs management
- Change control management
- Suppliers management
- GMP training

Regulatory

- Regulatory documentation (DMFs, CEPs, Abridged Dossiers)
- SMF management
- Change Control assessment



...resulting in excellent regulatory reputation

GMP inspection date	Regulatory Agency	Country
11-15 May 2019	FDA	USA
18-21 October 2011	AIFA	Italy
24-26 October 2012	AIFA	Italy
12-16 November 2012	FDA	USA
21-25 September 2015	AIFA	Italy
15-19 February 2016	FDA	USA



.... And strong attention to HSE - Environmental certification ISO 14001:2015



CERTIFICATO n. CERTIFICATE No

2429

BI CERTIFICA CHE L'ORGANIZZAZIONE WE HEREBY CERTIFY THAT THE ORGANIZATION



HUVEPHARMA ITALIA S.r.I.

IT - 12075 GARESSIO (CN) - VIA R.LEPETIT 142

NEI BEGLIENTS SITE! WITHE FOLLOWING SITES IT - 12075 GARESSIO (CN) - VIA R. LEPETIT 142

UNI EN ISO 14001:2015

PER LE SEGUENTI ATTINTA I POR THE POLLOWING ACTIVITIES COOR LAF 13, 12

Produzione di intermedi e principi attivi farmaceutici via sintesi chimica. Stoccaggio di materie prime sfuse ed a collettame. Stoccaggio e spedizione di prodotti finiti sfusi ed a collettame. Production of intermediates and pharmaceutical active ingredients by chemical synthesis. Stocking of raw materials, loose and packaged. Stocking and shipment of finished products, loose and packaged.

Confilinatione (Resolute in conformité al Regolumento Tecnico ACCREDIA RT 09 E. PRESENTE CERTIFICATO E DOGOETTO AL RISPETTO DEL RISPOLAMENTO PER LA CERTIFICAZIONE DEI BETRAI DI GESTIONE DEI LOS AND THE VALESTY OF THE CHITIFICATE DIALL SYSTEM THE REQUIREMENTS OF THE RILES FOR THE CERTIFICATION OF INALIZATION PROVINCIAL.

20/12/1999 06/02/2018

10/02/2021 06/02/2018







CERTIFICATE

CISQ/CERTIQUALITY S.r.I.

has issued an IQNet recognised certificate that the organization:

HUVEPHARMA ITALIA S.r.I.

IT - 12075 GARESSIO (CN) - VIA R.LEPETIT 142 for the following scope

Production of intermediates and pharmaceutical active ingredients by chemical synthesis. Stocking of raw materials, loose and packaged. Stocking and shipment of finished products, loose and packaged.

> has implemented and maintains a **Environmental Management System** ISO 14001:2015

Issued on: First issued on: 2018-02-06 1999-12-20

Expires on: 2021-02-10

This attestation is directly linked to the IQNet Partner's original certificate and shall not be used as a stand-alone document

Registration number: IT-10005

Alex Stoichitoiu President of IQNET

Ing. Claudio Provetti President of CISQ

AENOR, Spain AFNOR Certification France APCER Pertuguit CCC Cyprus CISQ Italy
CQC Chinu CQM Chinu CQS Czech Republic Cor Cent Counts DQS Holding Gmibli Germany FCAV Brazil
FONDONORMA Femselet ICONTEC Colombia Importa Sertificini Oy Finland INTECO Core Britis
RRM Argunita DA, Jajan KFO, Korran MIRTEC Greene MSZT Hangary Nemboa Set Norway MSRA Ireland
NYCE-SIGE Africa PCEC Poland Quality Austria clerivia RR, Results SII Irraci SIQ Slowenia
M QAS International Molopius SiQS Setterband SRAC Remoint IETS To FeterSouth Results TSE Tarkey VLOS Serbia
IQNet in represented in the USA by: AFNOR Certification, CISQ, DQS Holding GmibH and NSAI Inc.

* The list of KONet purtners is valid at the time of issue of this certificate. Updated information is available under www.iquet-certification.com







.... And strong attention to HSE - Safety certification ISO 18001:2007



CERTIFICATE

IQNet and its partner CISQ/CERTIQUALITY S.r.I.

HUVEPHARMA ITALIA S.r.I.

IT - 20079 SAN DONATO MILANESE (MI) - VIALE DELLA LIBERTA' 80

has implemented and maintains a Safety Management System

OH SAS 18001:2007

Code IAF 12 for the following activities

Production of intermediates and active pharmaceutical ingredients.

IT - 12075 GARESSIO (CN) - ROBERTO LEPETIT 142

Issued on: 2015-09-26 Certified since: 2007-12-13

2019-08-02 Registration number: IT-62306

Or Secular

President of CISO

President of IONET

AENOR Spain AFNOR Certification France AIB-Vincotte International Belgium APCER Portugal CCC Cyprus PECAVIS Spain AFRANCE CHIMICARON CARD AND ANICONE MEMBRANDA SPAIN AFRANCE POPULAR CARD AND ANICONE AND ANICONE AND ANICONE ANI SQS Switzerland SRAC Romania TEST St Petersburg Russia TSE Turkey YUQS Serbia IQNet is represented in the USA by: AFNOR Certification, CISQ, DQS Holding GmbH and NSAI Inc.

* The list of IQNet partners is valid at the time of issue of this certificate. Updated information is available under www.iquet-certification.com





.... And strong attention to HSE - Seveso certification UNI 10617



23818

CISQ is a member of

SI CERTIFICA CHE L'ORGANIZZAZIONE WE HEREBY CERTIFY THAT THE ORGANIZATION

HUVEPHARMA ITALIA S.r.I.

IT - 20079 SAN DONATO MILANESE (MI) - VIALE DELLA LIBERTA' 80

NEI SEGLENTI SITLI IN THE FOLLOWING SITES IT - 12075 GARESSIO (CN) - ROBERTO LEPETIT 142

UNI 10617

PER LE SEQUENTI ATTIMITÀ I FOR THE FOLLOWING ACTIVITIES SORE LAF 13

Produzione intermedi e principi attivi farmaceutici. Production of intermediates and pharmaceutical active ingredients.

IL PRESENTE CERTIFICATO EI BOGGETTO AL RISPETTO DEL REQUIAMENTO PER LA CERTIFICAZIONE DEI BIETONI DI DESTINUÈ THE USE AND THE WALDITY OF THE CHYTRICATE SHALL SATINY THE INIGINEMENTS OF THE MALES FOR THE CHITZPICATION OF MANAGEMENT SYSTEMS

03/08/2016 26/09/2016 01/09/2018





... And strong attention to HSE - ECOVADIS 2018 evaluation






5 | Product Portfolio





Product Portfolio

Consolidated product portfolio





Product Portfolio

Active Ingredients

• Artesunate • anti-malaria CAS n. 88495-63-0	Filed to FDA, WHO approved
Oxybutynin HCI • anticholinergic CAS n. 1508-65-2	PMDA accredited
Antiepileptic •toll manufacturing	FDA approved
• Artemether • anti-malaria CAS n. 71963-77-4	WHO approved
ASK2 - Potassium N-acetylaminosuccinate nootropic CAS n. 3397-52-2	
Tiapride HCI neurological and psychiatric disorders CAS n. 5	1012-33-0 CEP available
•antipsychotic CAS n. 15676-16-1	CEP available
Halofuginone •captive use	
Ractopamine • captive use	
Deflazacort •anti inflammatory CAS n. 14484-47-0 dev. phas	se



Product Portfolio Intermediates

Chloro 2 phenothiazine

•CAS n. 92-39-7 (Choropromazine/Cyamemazine)

Semisynthetic Artemisinin

•CAS n. 63968-64-9 (antimalaria APIs)

WHO approved

Cis triol acetonide

•CAS n. 52187-19-6 (Nadolol)

Cortiseven

•CAS n. 21269-13-6 (Deflazacort)

Ramipril Precursor 1

• CAS n. 82717-96-2 (Ramipril, Enalapril, etc.)

Thiophene Ester Base

•CAS n. 85006-31-1 (Articaine)

Food Fragrance

• (toll manufacturing)

Anidulafungin

•CAS n. 166663-25-8 (anti-fungal)

Azacyclonol free base

•CAS n. 115-46-8 (Fexofenadine)



Distribution

Experienced export organization





6 | Conclusion





Our Competitive Advantage

Huvepharma Italia is a recognized partner offering:

Excellent regulatory reputation

 Sites that operate under high quality standards (FDA & AIFA approvals; OHSAS 18001 & ISO 14001 certifications)

Flexible & fast response

 Consolidated experience in collecting all data & process information from the start for easy regulatory submission.

Chemistry & fermentation cost competitive expertise

- Strong experience in implementing new productions & new technologies
- In addition to Garessio facility expertise in chemical synthesis, Huvepharma Italia takes advantage of the fermentation expertise & cost effectiveness of the Bulgarian manufacturing plants.

Confidentiality

A key policy of the Huvepharma Group



THANK YOU FOR YOUR ATTENTION



